{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:31:13Z","timestamp":1789579873728,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum D\u00fcsseldorf. Anstalt \u00f6ffentlichen Rechts"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoantigens derived from tumour-specific mutations are critical targets for T-cell recognition, yet the relationship between neoantigen clonality and immune response in head and neck squamous cell carcinoma (HNSCC) remains poorly understood. We hypothesised that clonal neoantigens, being present in all tumour cells, would drive T-cell exhaustion through persistent antigen exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed 527 HNSCC tumours from The Cancer Genome Atlas. Neoantigens were predicted using pVACseq with MHCflurry binding prediction for patient-specific HLA class I alleles. We computed a Clonality Score (binder-weighted variant allele frequency normalised by neoantigen count) to quantify clonal origin independent of total burden. T-cell exhaustion was assessed using a 17-gene expression signature, alongside TIDE dysfunction scores and the Pan-Immune Score. Cox proportional hazards models with interaction terms tested whether prognostic effects of clonality depended on immune context.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Contrary to our hypothesis, neoantigen clonality showed strong inverse correlations with T-cell infiltration-associated signatures, including a 17-gene exhaustion\/activation panel (\u03c1 = \u22120.41, P\u2009=\u20099.8\u2009\u00d7\u200910\u207b\u00b2\u00b2), TIDE dysfunction (\u03c1 = \u22120.53, P\u2009=\u20096.7\u2009\u00d7\u200910\u207b\u00b3\u2078), and Pan-Immune Score (\u03c1 = \u22120.50, P\u2009=\u20098.5\u2009\u00d7\u200910\u207b\u00b3\u00b3). Tumours stratified into four phenotypes: Hot\/Low Clonality (33%) exhibited high immune infiltration and cytolytic activity; Cold\/High Clonality (33%) showed minimal immune engagement despite abundant clonal neoantigens. High clonality also associated with reduced antigen presentation machinery expression (\u03c1 = \u22120.31, P\u2009=\u20091.0\u2009\u00d7\u200910\u207b\u00b9\u00b2), suggesting impaired antigen visibility as a potential upstream mechanism. Survival analysis revealed a significant clonality \u00d7 immune status interaction (P\u2009=\u20090.034). In \u2018hot\u2019 tumours, high clonality predicted improved survival (HR\u2009=\u20090.72, P\u2009=\u20090.043), whereas clonality had no prognostic effect in \u2018cold\u2019 tumours (HR\u2009=\u20091.00,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.98).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Neoantigen clonality inversely predicts T-cell activity in HNSCC, identifying high-clonality tumours as immunologically \u2018cold\u2019 despite abundant tumour-specific antigens. Crucially, the prognostic benefit of clonality is realised only when T-cell effectors are present, reconciling our findings with the paradigm that clonal neoantigens represent optimal immunological targets. This context-dependent relationship generates the hypothesis that neoantigen clonality, when interpreted alongside immune context, may help identify patients who could benefit from immune-priming strategies prior to checkpoint inhibitor therapy, pending validation in immunotherapy-treated cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08371-z","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:36:15Z","timestamp":1780472175000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inverse relationship between neoantigen clonality and T-cell activity reveals distinct immune phenotypes in HNSCC"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2298-3696","authenticated-orcid":false,"given":"Babak","family":"Saravi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daman Deep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Schorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Lommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Wilkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Vollmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"H\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaustubh","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Roider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Wollborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"K\u00fcbler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Sproll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"1","key":"8371_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. https:\/\/doi.org\/10.1038\/s41572-020-00224-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"8371_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660. PubMed PMID: 33538338.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"8371_CR3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41415-022-5166-x","volume":"233","author":"M Gormley","year":"2022","unstructured":"Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233(9):780\u20136. https:\/\/doi.org\/10.1038\/s41415-022-5166-x. PubMed PMID: 36369568; PubMed Central PMCID: PMC9652141.","journal-title":"Br Dent J"},{"issue":"2","key":"8371_CR4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/medsci11020042","volume":"11","author":"A Barsouk","year":"2023","unstructured":"Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A, Epidemiology. Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci (Basel). 2023;11(2):42. https:\/\/doi.org\/10.3390\/medsci11020042. PubMed PMID: 37367741; PubMed Central PMCID: PMC10304137.","journal-title":"Med Sci (Basel)"},{"issue":"19","key":"8371_CR5","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375(19):1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252. PubMed PMID: 27718784; PubMed Central PMCID: PMC5564292.","journal-title":"N Engl J Med"},{"issue":"10212","key":"8371_CR6","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(. 19)32591-7 PubMed PMID: 31679945.","journal-title":"Lancet"},{"issue":"6230","key":"8371_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69\u201374. https:\/\/doi.org\/10.1126\/science.aaa. 4971 PubMed PMID: 25838375.","journal-title":"Science"},{"issue":"4","key":"8371_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/s41573-021-00387","volume":"21","author":"F Lang","year":"2022","unstructured":"Lang F, Schr\u00f6rs B, L\u00f6wer M, T\u00fcreci \u00d6, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov. 2022;21(4):261\u201382. https:\/\/doi.org\/10.1038\/s41573-021-00387. y PubMed PMID: 35105974; PubMed Central PMCID: PMC7612664.","journal-title":"Nat Rev Drug Discov"},{"key":"8371_CR9","doi-asserted-by":"publisher","unstructured":"McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139. https:\/\/doi.org\/10.1126\/science.aaf1490. PubMed PMID: 26940869; PubMed Central PMCID: PMC4984254.","DOI":"10.1126\/science.aaf1490"},{"issue":"1","key":"8371_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.cell.2019.08.032","volume":"179","author":"Y Wolf","year":"2019","unstructured":"Wolf Y, Bartok O, Patkar S, Eli GB, Cohen S, Litchfield K, et al. UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma. Cell. 2019;179(1):219\u2013e23521. https:\/\/doi.org\/10.1016\/j.cell.2019.08.032. PubMed PMID: 31522890; PubMed Central PMCID: PMC6863386.","journal-title":"Cell"},{"issue":"10","key":"8371_CR11","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-019-0592-2","volume":"25","author":"K Joshi","year":"2019","unstructured":"Joshi K, de Massy MR, Ismail M, Reading JL, Uddin I, Woolston A, et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat Med. 2019;25(10):1549\u201359. https:\/\/doi.org\/10.1038\/s41591-019-0592-2. PubMed PMID: 31591606; PubMed Central PMCID: PMC6890490.","journal-title":"Nat Med"},{"issue":"7681","key":"8371_CR12","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature24473","volume":"551","author":"M \u0141uksza","year":"2017","unstructured":"\u0141uksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, et al. A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. Nature. 2017;551(7681):517\u201320. https:\/\/doi.org\/10.1038\/nature24473. PubMed PMID: 29132144; PubMed Central PMCID: PMC6137806.","journal-title":"Nature"},{"key":"8371_CR13","doi-asserted-by":"publisher","unstructured":"Alban TJ, Riaz N, Parthasarathy P, Makarov V, Kendall S, Yoo SK, et al. Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumab. Nat Med. 2024;30(11):3209\u201322. https:\/\/doi.org\/10.1038\/s41591-024-03240-y. PubMed PMID: 39349627; PubMed Central PMCID: PMC12066197.","DOI":"10.1038\/s41591-024-03240-y"},{"issue":"8","key":"8371_CR14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486\u201399. doi:10.1038\/nri3862 PubMed PMID: 26205583; PubMed Central PMCID: PMC4889009.","journal-title":"Nat Rev Immunol"},{"key":"8371_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-immunol-041015","volume":"37","author":"LM McLane","year":"2019","unstructured":"McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol. 2019;37:457\u201395. https:\/\/doi.org\/10.1146\/annurev-immunol-041015. -055318 PubMed PMID: 30676822.","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"8371_CR16","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","volume":"45","author":"A Schietinger","year":"2016","unstructured":"Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, et al. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis. Immunity. 2016;45(2):389\u2013401. https:\/\/doi.org\/10.1016\/j.immuni.2016.07.011. PubMed PMID: 27521269; PubMed Central PMCID: PMC5119632.","journal-title":"Immunity"},{"key":"8371_CR17","doi-asserted-by":"publisher","first-page":"995434","DOI":"10.3389\/fonc.2022.995434","volume":"12","author":"Z Chen","year":"2022","unstructured":"Chen Z, John J, Wang JH. Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factors. Front Oncol. 2022;12:995434. https:\/\/doi.org\/10.3389\/fonc.2022.995434. PubMed PMID: 36330485; PubMed Central PMCID: PMC9623029.","journal-title":"Front Oncol"},{"issue":"Pt 2","key":"8371_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.semcancer.2018.01.008","volume":"52","author":"B Solomon","year":"2018","unstructured":"Solomon B, Young RJ, Rischin D. Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 2018;52(Pt 2):228\u201340. https:\/\/doi.org\/10.1016\/j.semcancer.2018.01.008. PubMed PMID: 29355614.","journal-title":"Semin Cancer Biol"},{"issue":"7536","key":"8371_CR19","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576\u201382. doi:10.1038\/nature14129 PubMed PMID: 25631445; PubMed Central PMCID: PMC4311405.","journal-title":"Nature"},{"issue":"7","key":"8371_CR20","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/1878-0261.12895","volume":"15","author":"X Li","year":"2021","unstructured":"Li X, Zhou C, Chen K, Huang B, Liu Q, Ye H. Benchmarking HLA genotyping and clarifying HLA impact on survival in tumor immunotherapy. Mol Oncol. 2021;15(7):1764\u201382. https:\/\/doi.org\/10.1002\/1878-0261.12895. PubMed PMID: 33411982; PubMed Central PMCID: PMC8253103.","journal-title":"Mol Oncol"},{"issue":"6","key":"8371_CR21","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","volume":"171","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017;171(6):1259\u2013e127111. https:\/\/doi.org\/10.1016\/j.cell.2017.10.001. PubMed PMID: 29107330; PubMed Central PMCID: PMC5720478.","journal-title":"Cell"},{"issue":"4","key":"8371_CR22","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, et al. The Immune Landscape of Cancer. Immunity. 2018;48(4):812\u2013e83014. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.023.","journal-title":"Immunity"},{"issue":"5","key":"8371_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337. PubMed PMID: 25822800; PubMed Central PMCID: PMC4739640.","journal-title":"Nat Methods"},{"issue":"10","key":"8371_CR24","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1038\/s41591-018-0136-1","volume":"24","author":"P Jiang","year":"2018","unstructured":"Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0136-1. PubMed PMID: 30127393; PubMed Central PMCID: PMC6487502.","journal-title":"Nat Med"},{"issue":"1","key":"8371_CR25","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann A, et al. The Ensembl Variant Effect Predictor. Genome Biol. 2016;17(1):122. https:\/\/doi.org\/10.1186\/s13059-016-0974-4. PubMed PMID: 27268795; PubMed Central PMCID: PMC4893825.","journal-title":"Genome Biol"},{"issue":"1","key":"8371_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13073-016-0264-5","volume":"8","author":"J Hundal","year":"2016","unstructured":"Hundal J, Carreno BM, Petti AA, Linette GP, Griffith OL, Mardis ER, et al. pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med. 2016;8(1):11. https:\/\/doi.org\/10.1186\/s13073-016-0264-5.","journal-title":"Genome Med"},{"issue":"1","key":"8371_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.cels.2018.05.014","volume":"7","author":"TJ O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell TJ, Rubinsteyn A, Bonsack M, Riemer AB, Laserson U, Hammerbacher J. MHCflurry: Open-Source Class I MHC Binding Affinity Prediction. Cell Syst. 2018;7(1):129\u2013e1324. https:\/\/doi.org\/10.1016\/j.cels.2018.05.014. PubMed PMID: 29960884.","journal-title":"Cell Syst"},{"key":"8371_CR28","doi-asserted-by":"publisher","unstructured":"Budhwani M, Turrell G, Yu M, Frazer IH, Mehdi AM, Chandra J. Immune-Inhibitory Gene Expression is Positively Correlated with Overall Immune Activity and Predicts Increased Survival Probability of Cervical and Head and Neck Cancer Patients. Front Mol Biosci. 2021;8:622643. https:\/\/doi.org\/10.3389\/fmolb.2021.622643.","DOI":"10.3389\/fmolb.2021.622643"},{"issue":"1","key":"8371_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","volume":"18","author":"P Charoentong","year":"2017","unstructured":"Charoentong P, Finotello F, Angelova M, Mayer C, Efremova M, Rieder D, et al. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 2017;18(1):248\u201362. https:\/\/doi.org\/10.1016\/j.celrep.2016.12.019. PubMed PMID: 28052254.","journal-title":"Cell Rep"},{"issue":"5","key":"8371_CR30","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nbt.2203","volume":"30","author":"SL Carter","year":"2012","unstructured":"Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol. 2012;30(5):413\u201321. https:\/\/doi.org\/10.1038\/nbt.2203. PubMed PMID: 22544022; PubMed Central PMCID: PMC4383288.","journal-title":"Nat Biotechnol"},{"issue":"7749","key":"8371_CR31","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567(7749):479\u201385. https:\/\/doi.org\/10.1038\/s41586-019-1032-7. PubMed PMID: 30894752; PubMed Central PMCID: PMC6954100.","journal-title":"Nature"},{"issue":"6024","key":"8371_CR32","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion. Science. 2011;331(6024):1565\u201370. https:\/\/doi.org\/10.1126\/science.1203486. PubMed PMID: 21436444.","journal-title":"Science"},{"issue":"4","key":"8371_CR33","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/imm.13114","volume":"158","author":"F Garrido","year":"2019","unstructured":"Garrido F, Aptsiauri N. Cancer immune escape: MHC expression in primary tumours versus metastases. Immunology. 2019;158(4):255\u201366. doi:10.1111\/imm.13114 PubMed PMID: 31509607; PubMed Central PMCID: PMC6856929.","journal-title":"Immunology"},{"key":"8371_CR34","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021;12:636568. https:\/\/doi.org\/10.3389\/fimmu. 2021.636568 PubMed PMID: 33767702; PubMed Central PMCID: PMC7986854.","journal-title":"Front Immunol"},{"issue":"5","key":"8371_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41568-021","volume":"21","author":"S Jhunjhunwala","year":"2021","unstructured":"Jhunjhunwala S, Hammer C, Delamarre L. Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion. Nat Rev Cancer. 2021;21(5):298\u2013312. https:\/\/doi.org\/10.1038\/s41568-021. 00339-z PubMed PMID: 33750922.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"8371_CR36","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1158\/2159-8290.CD-17-0593","volume":"7","author":"S Gettinger","year":"2017","unstructured":"Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, et al. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017;7(12):1420\u201335. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0593. PubMed PMID: 29025772; PubMed Central PMCID: PMC5718941.","journal-title":"Cancer Discov"},{"key":"8371_CR37","doi-asserted-by":"publisher","unstructured":"Davoli T, Uno H, Wooten EC, Elledge SJ. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science. 2017;355(6322):eaaf8399. https:\/\/doi.org\/10.1126\/science.aaf8399. PubMed PMID: 28104840; PubMed Central PMCID: PMC5592794.","DOI":"10.1126\/science.aaf8399"},{"issue":"3","key":"8371_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197\u2013218. https:\/\/doi.org\/10.1038\/s41573-018-0007. -y PubMed PMID: 30610226.","journal-title":"Nat Rev Drug Discov"},{"issue":"7637","key":"8371_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330. https:\/\/doi.org\/10.1038\/nature21349. PubMed PMID: 28102259.","journal-title":"Nature"},{"issue":"2","key":"8371_CR40","doi-asserted-by":"publisher","first-page":"e70175","DOI":"10.1002\/ctm2","volume":"15","author":"H Ke","year":"2025","unstructured":"Ke H, Li P, Li Z, Zeng X, Zhang C, Luo S, et al. Immune profiling of the macroenvironment in colorectal cancer unveils systemic dysfunction and plasticity of immune cells. Clin Transl Med. 2025;15(2):e70175. https:\/\/doi.org\/10.1002\/ctm2. 70175 PubMed PMID: 39934971; PubMed Central PMCID: PMC11813809.","journal-title":"Clin Transl Med"},{"key":"8371_CR41","doi-asserted-by":"publisher","first-page":"goad034","DOI":"10.1093\/gastro\/goad034","volume":"11","author":"H Ke","year":"2023","unstructured":"Ke H, Li Z, Li P, Ye S, Huang J, Hu T, et al. Dynamic heterogeneity of colorectal cancer during progression revealed clinical risk-associated cell types and regulations in single-cell resolution and spatial context. Gastroenterol Rep (Oxf). 2023;11:goad034. https:\/\/doi.org\/10.1093\/gastro\/goad034. PubMed PMID: 37360193; PubMed Central PMCID: PMC10290555.","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"25","key":"8371_CR42","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017;377(25):2500\u20131. doi:10.1056\/NEJMc1713444 PubMed PMID: 29262275; PubMed Central PMCID: PMC6549688.","journal-title":"N Engl J Med"},{"issue":"11","key":"8371_CR43","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.7150\/thno.58390","volume":"11","author":"YT Liu","year":"2021","unstructured":"Liu YT, Sun ZJ. Turning cold tumors into hot tumors by improving T-cell infiltration. Theranostics. 2021;11(11):5365\u201386. 10. 7150\/thno.58390 PubMed PMID: 33859752; PubMed Central PMCID: PMC8039952.","journal-title":"Theranostics"},{"key":"8371_CR44","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","volume":"10","author":"P Bonaventura","year":"2019","unstructured":"Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, et al. Cold Tumors: A Therapeutic Challenge for Immunotherapy. Front Immunol. 2019;10:168. https:\/\/doi.org\/10.3389\/fimmu.2019.00168. PubMed PMID: 30800125; PubMed Central PMCID: PMC6376112.","journal-title":"Front Immunol"},{"issue":"1","key":"8371_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-T\u00e2n PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24\u201335. https:\/\/doi.org\/10.1056\/NEJMoa0912217. PubMed PMID: 20530316; PubMed Central PMCID: PMC2943767.","journal-title":"N Engl J Med"},{"issue":"3","key":"8371_CR46","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/nri","volume":"18","author":"Z Hu","year":"2018","unstructured":"Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168\u201382. https:\/\/doi.org\/10.1038\/nri. 2017.131 PubMed PMID: 29226910; PubMed Central PMCID: PMC6508552.","journal-title":"Nat Rev Immunol"},{"issue":"16suppl","key":"8371_CR47","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1200\/JCO.2022.40.16_suppl.2637","volume":"40","author":"JP Delord","year":"2022","unstructured":"Delord JP, Block MS, Ottensmeier C, Colon-Otero G, Le Tourneau C, Lalanne A, et al. Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC). JCO. 2022;40(16suppl):2637\u20132637. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.2637.","journal-title":"JCO"},{"issue":"4","key":"8371_CR48","doi-asserted-by":"publisher","first-page":"274","DOI":"10.20892\/j.issn.2095-3941.2023.0395","volume":"21","author":"X Li","year":"2023","unstructured":"Li X, You J, Hong L, Liu W, Guo P, Hao X. Neoantigen cancer vaccines: a new star on the horizon. Cancer Biol Med. 2023;21(4):274\u2013311. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0395. PubMed PMID: 38164734; PubMed Central PMCID: PMC11033713.","journal-title":"Cancer Biol Med"},{"key":"8371_CR49","doi-asserted-by":"publisher","unstructured":"Wang CC, Wang CC, Yang CC, Hwang TZ, Lien CF, Shih YC, et al. Fully COVID-19 vaccinated status enhanced the efficacy of immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma. Head Neck. 2025 Nov;19. https:\/\/doi.org\/10.1002\/hed.70104. PubMed PMID: 41261809.","DOI":"10.1002\/hed.70104"},{"issue":"8089","key":"8371_CR50","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-025-09655-y","volume":"647","author":"AJ Grippin","year":"2025","unstructured":"Grippin AJ, Marconi C, Copling S, Li N, Braun C, Woody C, et al. SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade. Nature. 2025;647(8089):488\u201397. https:\/\/doi.org\/10.1038\/s41586-025-09655-y.","journal-title":"Nature"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08371-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08371-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08371-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:06:17Z","timestamp":1780495577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08371-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8371"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08371-z","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"731"}}